The possibilities of pharmacological regulation of the processes of adaptation to dental constructions

The aim of the work was to study the antihypoxic properties of a number of complex zinc-containing compounds of nicotinic acid under the code πQ. The experiments were performed on male mice of the SHR line. Antihypoxic properties of compounds were studied on 4 models of acute hypoxia (hypoxia with hypercapnia, hypobaric, hemic, and histotoxic). It was found that the compound πQ-1043 in the dose spectrum of 10-100 mg/kg effectively increases the life expectancy of animals in all models of acute hypoxia. The compound πQ-1043 at a dose of 25 mg/kg reduces the oxygen consumption and rectal temperature of animals, which can be a key factor in its anti-hypoxic action. The compound does not change glycolytic carbohydrate metabolism in animals under normal conditions, but corrects these changes in acute hypoxia. Substance πQ-1043 maintains a high content in the blood of erythrocytes and hemoglobin under hypoxic conditions. The lethal dose 50 of the compound πQ-1043 applies to moderately toxic chemicals. It is assumed that the complex zinc-containing derivative of nicotinic acid πQ-1043 is a promising compound for the development of an effective drug for the correction of hypoxic states of different genesis.

Section: Introductionunclassified

Promising antihypoxant in a range of complex zinc-containing derivatives of nicotinic acid

Гнеушев

Михайлович²,

Pozhilova

et al. 2019

“…В последние годы в медицинскую практику активно внедряются лекарственные препараты с антигипоксическими свойствами [15,19]. Ме-таболические корректоры гипоксии применяют при многих заболеваниях, в генезе которых присутствуют состояния гипоксии и ишемии [7,8,14].…”

Section: Introductionunclassified

The impact of the new derivative of nicotinic acid with anti-hypoxic activity on the functions of the central nervous system

Гнеушев

Михайлович²,

Катунина

et al. 2019

The aim of the work was to study the effect of the complex compound of nicotine acid with antihypoxic activity under the code πQ-1043 on the function of the central nervous system. The experiments were performed on male mice of the SHR line. Influence of the compound on the function of the central nervous system was evaluated in the tests “open field”, conditioned-defense reflex of avoidance and corazole seizures. It was found that the compound πQ-1043 at a dose of 25 mg/kg increases emotional reactivity and reduces the coefficient of mobility of mice in the “open field” test, increases the latent time of the conditionally defensive reflex of avoidance, inhibits the development of seizures and increases the life expectancy of animals after administration of corazole. Such changes in the studied parameters indicate that the compound πQ-1043 has a depressing effect on the central nervous system function. It is assumed that the identified effect may be one of the components in the mechanism of antihypoxic action of the compound.

The effect of neuropeptide ACTH4-10 on the adaptation of patients to dental prostheses according to the data of monitoring the emotional state using a polygraph

Pozhilova

Егорович²,

Евсеев³

et al. 2022

BACKGROUND: Monitoring and pharmacological correction of adaptation of patients to full removable dental prostheses is actual and practically important problem in stomatology. AIM: To study the effect of neuropeptide ACTH4-10 on the process of adaptation of patients to complete removable prostheses by monitoring the emotional state using a polygraph. MATERIALS AND METHODS: Examination and primary prosthetics with full removable dentures of patients (6075 years old) were performed of both sexes with total adentia. All patients were divided into three groups: the main group (correction of the adaptation process with ACTH4-10 neuropeptide Semax 0.1% nasal drops), the comparison group (0.9% NaCl solution was administered intranasally) and the control group (without pharmacological correction). Monitoring of the process of adaptation to prostheses was carried out by registering the emotional reaction of patients to the movements of the lower jaw with the help of a polygraph Barrier-14 of the company Antey (Russia). RESULTS: The emotional state of patients in the main observation group who received pharmacological correction with ACTH4-10 neuropeptide reaches the values of adapted patients for most of the studied indicators within 714 days after the application of prostheses, and a month after the application of prostheses - for all studied indicators of the curves of the trajectories of the lower jaw (p 0.05), which cannot be noted in patients of the comparison group (NaCl) and the control group. The results obtained indicate a positive effect of the neuropeptide ACTH4-10 on the process of getting used to patients with complete removable prostheses. CONCLUSIONS: Neuropeptide ACTH4-10 accelerates the process of adaptation of primary prosthetic patients to complete removable dental prostheses according to the monitoring of the emotional background of patients. The method of registering the emotional state of patients using a polygraph allows us to make an objective conclusion about the effect of occlusion and articulation on the psycho-emotional background and judge the patient's adaptation to a dental prosthesis.